-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.
-
Summary
-
Vertex Pharmaceuticals Inc / Ma quarterly/annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest history and growth rate from Q3 2013 to Q3 2025.
- Vertex Pharmaceuticals Inc / Ma Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for the quarter ending September 30, 2025 was $1.3B, a 6.1% increase year-over-year.
- Vertex Pharmaceuticals Inc / Ma Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for the twelve months ending September 30, 2025 was $4.45B, a 1614% increase year-over-year.
- Vertex Pharmaceuticals Inc / Ma annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for 2024 was $249M, a 94.3% decline from 2023.
- Vertex Pharmaceuticals Inc / Ma annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for 2023 was $4.38B, a 3.48% increase from 2022.
- Vertex Pharmaceuticals Inc / Ma annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for 2022 was $4.23B, a 55% increase from 2021.
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, Trailing 12 Months (USD)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, Quarterly (USD)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, YoY Quarterly Growth (%)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, Annual (USD)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, YoY Annual Growth (%)